Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Kovack Advisors Inc.

Kovack Advisors Inc. cut its position in Moderna, Inc. (NASDAQ:MRNA) by 19.6% in the fourth quarter, Holdings Channel reports. The firm owned 2,708 shares of the company’s stock after selling 662 shares during the period. Kovack Advisors Inc.’s holdings in Moderna were worth $269,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in the company. International Assets Investment Management LLC increased its holdings in shares of Moderna by 6,528.9% in the 4th quarter. International Assets Investment Management LLC now owns 387,656 shares of the company’s stock valued at $38,552,000 after acquiring an additional 381,808 shares during the period. abrdn plc boosted its stake in shares of Moderna by 477.5% during the fourth quarter. abrdn plc now owns 483,574 shares of the company’s stock worth $48,091,000 after buying an additional 399,843 shares during the period. Invesco Ltd. grew its holdings in shares of Moderna by 19.8% during the third quarter. Invesco Ltd. now owns 3,126,028 shares of the company’s stock worth $322,887,000 after buying an additional 517,683 shares during the last quarter. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD increased its position in Moderna by 10.5% in the 3rd quarter. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD now owns 32,188 shares of the company’s stock valued at $3,252,000 after acquiring an additional 3,052 shares during the period. Finally, Cadinha & Co. LLC raised its stake in Moderna by 109.0% during the 4th quarter. Cadinha & Co. LLC now owns 81,838 shares of the company’s stock valued at $8,139,000 after acquiring an additional 42,685 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Stock Up 3.4 %

MRNA stock opened at $111.62 on Tuesday. The company has a current ratio of 3.42, a quick ratio of 3.36 and a debt-to-equity ratio of 0.04. The company’s 50 day simple moving average is $103.01 and its 200-day simple moving average is $93.71. Moderna, Inc. has a 12 month low of $62.55 and a 12 month high of $142.79.

Moderna (NASDAQ:MRNA) last posted its earnings results on Thursday, February 22nd. The company reported $0.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.78) by $1.33. Moderna had a negative return on equity of 10.23% and a negative net margin of 68.84%. The firm had revenue of $2.80 billion for the quarter, compared to analyst estimates of $2.53 billion. During the same quarter in the prior year, the company earned $3.61 EPS. Moderna’s revenue was down 44.9% on a year-over-year basis. On average, sell-side analysts anticipate that Moderna, Inc. will post -7.51 EPS for the current year.

Insider Buying and Selling

In other Moderna news, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction dated Wednesday, March 13th. The shares were sold at an average price of $108.54, for a total value of $1,628,100.00. Following the transaction, the director now directly owns 2,131,931 shares in the company, valued at approximately $231,399,790.74. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, CFO James M. Mock sold 705 shares of the firm’s stock in a transaction on Monday, April 8th. The stock was sold at an average price of $101.93, for a total transaction of $71,860.65. Following the sale, the chief financial officer now owns 5,048 shares in the company, valued at $514,542.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction on Wednesday, March 13th. The shares were sold at an average price of $108.54, for a total value of $1,628,100.00. Following the completion of the transaction, the director now owns 2,131,931 shares of the company’s stock, valued at $231,399,790.74. The disclosure for this sale can be found here. In the last quarter, insiders sold 124,954 shares of company stock worth $13,158,776. 15.20% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

MRNA has been the topic of a number of recent research reports. Canaccord Genuity Group boosted their target price on Moderna from $82.00 to $91.00 and gave the company a “hold” rating in a report on Friday, February 23rd. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a research note on Thursday, April 11th. Royal Bank of Canada restated an “outperform” rating and set a $125.00 price objective on shares of Moderna in a research report on Thursday, March 28th. William Blair reaffirmed a “market perform” rating on shares of Moderna in a report on Monday, April 1st. Finally, HSBC reiterated a “reduce” rating and set a $86.00 price target (up from $75.00) on shares of Moderna in a research note on Monday, February 26th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $126.49.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.